RxDoctor Payments Data

George Salama, MD

Urology · Florence, SCNPI 1841685146

Payments from drug & device makers

$4,328in general payments, 2019–2025

Across 96 payments — averaging $45.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Boston Scientific$1K
  • Teleflex LLC$525
  • AbbVie$210
  • Medtronic$202
  • Procept Biorobotics Corporation$164
  • plus $818 from 21 others

What the payments were for

  • Travel & lodging$1,18427%
  • Food & beverage$2,94268%
  • Education$2025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,328 in reported general payments places this provider in the 55th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$310,595
Medicare patients
592
Services billed
7,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide40$536,158
GemtesaVibegron145$92,230
MyrbetriqMirabegron67$35,616
Abiraterone Acetate16$11,766
Mirabegron ErMirabegron14$4,403
Tamsulosin Hcl426$3,396
Estradiol50$2,875
Tolterodine Tartrate ErTolterodine Tartrate45$2,500
Fesoterodine Fumarate ErFesoterodine Fumarate17$1,919
Ondansetron OdtOndansetron162$1,836
Trimethoprim27$1,654
Cefdinir125$1,356
Finasteride124$1,174
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$1,155
Solifenacin Succinate47$1,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$51$571,774107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 196 urology providers in South Carolina.

Other urology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →